Yaz® Birth Control Injury Lawyers
In light of the thousands of women who suffered blood clotting events (pulmonary embolisms and deep vein thrombosis) and other life-threatening injuries associated with Yaz® (drospirenone and ethinyl estradiol), Yasmin® (drospirenone and ethinyl estradiol), Ocella® (drospirenone and ethinyl estradiol), Beyaz® (ethinyl estradiol, drospirenone and levomefolic acid) and Gianvi® (drospirenone and ethinyl estradiol), the Judicial Panel on Multidistrict Litigation (JPML) consolidated cases filed against the manufacturer of these drugs in United States District Court for the Southern District of Illinois. In this litigation, known as the In re Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation, MDL 2100, Roger Denton of Schlichter Bogard & Denton was appointed by Judge Herndon as one of the select few counsel to lead the litigation. Under the leadership of Roger Denton and other attorneys, approximately 10,000 individual venous thrombotic cases have settled since March 2012, approximately 7,500 individual gallbladder cases settled in May 2014, and approximately 1,200 arterial thrombotic cases settled in July 2015. The global settlement totals approximately $1.6 billion.
In light of these settlements, Schlichter Bogard & Denton is no longer accepting Yaz, Yasmin, Ocella, Beyaz and Gianvi cases and therefore, the information on this page is provided for informational purposes.
Yaz, Yasmin, and the other birth control products listed above are different from other combination birth control pills because they both contain a progestin hormone known as drospirenone, or drsp. Drospirenone can cause an increase in the user’s potassium levels, which can lead to dangerous health problems. Researchers believe that drsp is to blame for the increased incidences of blood clots in Yaz, Yasmin, Ocella, Beyaz and Gianvi users.
According to a study published in 2009 by the British Medical Journal (BMJ), birth control pills containing drospirenone were associated with a significantly higher risk of venous thrombosis (blood clots within a vein) than birth control pills containing levonorgestrel, a different type of progestin. The results also showed that the overall risk of blood clots in women taking birth control pills was twice that of non-users. The study included women aged 15-49 who had no history of cardiovascular or malignant disease.
Another study published by the BMJ in 2011 further confirmed the findings from the 2009 study. The study included women aged 15-49 with no history of thrombotic disease who were followed from 2001 to 2009. The study found that users of birth control pills with drospirenone were “at least at twice the risk of venous thromboembolism compared with users of oral contraceptives with levonorgestrel.”